Market Place
Sourcing Support
EpiEndo reports Phase 2A results for lead asset, EP395, in COPD
10 Apr 2024 //
BUSINESSWIRE
EpiEndo commences Phase 2a trial for EP395 in COPD patients
14 Nov 2022 //
BUSINESSWIRE
EpiEndo begins trial of chronic obstructive pulmonary disease treatment
31 Aug 2022 //
CLINICALTRIALSARENA
EpiEndo commences LPS challenge trial for lead candidate EP395
31 Aug 2022 //
BUSINESSWIRE
EpiEndo successfully completes phase 1 study into respiratory treatment
18 May 2022 //
PHARMATIMES
EpiEndo: Successful Completion of Phase I Study for Lead Asset EP395
18 May 2022 //
BUSINESSWIRE
EpiEndo Pharma Expands its Leadership Team,;Appoints Stefan Petursson as CFO
24 Mar 2022 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.